论文部分内容阅读
目的探讨HIF-1α、VEGF在乳腺癌中的表达及其与新辅助化疗敏感性的关系。方法应用免疫组织化学S-P法检测52例乳腺癌患者新辅助化疗前、后瘤体组织HIF-1α、VEGF的表达,评估其与化疗疗效的关系。结果化疗前乳腺癌HIF-1α阳性表达为46.15%,化疗后降到21.15%,差异有统计学意义(P<0.05);VEGF的表达化疗前为55.77%,化疗后降到30.77%,差异有统计学意义(P<0.05)。化疗前后HIF-1α的表达与VEGF正相关,P<0.05。新辅助化疗前HIF-1α和VEGF表达阳性者均较阴性者化疗敏感性差,P<0.05。结论 HIF-1α和VEGF可作为乳腺癌化疗敏感性的预测因子,有助于制定个体化化疗方案。
Objective To investigate the expression of HIF-1α and VEGF in breast cancer and its relationship with the sensitivity of neoadjuvant chemotherapy. Methods The expressions of HIF-1α and VEGF in 52 cases of breast cancer before and after neoadjuvant chemotherapy were detected by immunohistochemical S-P method. The relationship between the expression of HIF-1α and VEGF was evaluated. Results The positive expression of HIF-1α in breast cancer before chemotherapy was 46.15%, and decreased to 21.15% after chemotherapy (P <0.05). The expression of VEGF was 55.77% before chemotherapy and 30.77% after chemotherapy, the difference was Statistical significance (P <0.05). The expression of HIF-1α before and after chemotherapy was positively correlated with VEGF (P <0.05). Before neoadjuvant chemotherapy, the positive expression of HIF-1α and VEGF were lower than that of negative ones, P <0.05. Conclusions HIF-1α and VEGF can be used as predictors of chemosensitivity in breast cancer and contribute to the development of personalized chemotherapy regimens.